ArticleLeukemia2012

The novel calicheamicin-conjugated CD22 antibody inotuzumab ozogamicin (CMC-544) effectively kills primary pediatric acute lymphoblastic leukemia cells.

J F de Vries et al.PubMed ↗Publisher ↗

No numbers read from the abstract.